Secondary (Hypogonadotropic) Hypogonadism Pipeline Review: H1 2018 - Covering Merck & Co, Mereo Biopharma Group and Repros Therapeutics - ResearchAndMarkets.com

June 11, 2018

DUBLIN--(BUSINESS WIRE)--Jun 11, 2018--The “Secondary (Hypogonadotropic) Hypogonadism - Pipeline Review, H1 2018” report has been added to ResearchAndMarkets.com’s offering.

This latest pipeline guide provides comprehensive information on the therapeutics under development for Secondary (Hypogonadotropic) Hypogonadism (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The pipeline guide also reviews of key players involved in therapeutic development for Secondary (Hypogonadotropic) Hypogonadism and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 1, 1 and 2 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Companies Mentioned

Merck & Co Inc Mereo Biopharma Group Plc Repros Therapeutics Inc

Key Topics Covered

Introduction Report Coverage Secondary (Hypogonadotropic) Hypogonadism - Overview Secondary (Hypogonadotropic) Hypogonadism - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Secondary (Hypogonadotropic) Hypogonadism - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Secondary (Hypogonadotropic) Hypogonadism - Companies Involved in Therapeutics Development Secondary (Hypogonadotropic) Hypogonadism - Drug Profiles

For more information about this report visit https://www.researchandmarkets.com/research/gdj5v7/secondary?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180611005920/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Endocrine and Metabolic Disorders Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 06/11/2018 01:02 PM/DISC: 06/11/2018 01:02 PM


Update hourly